nodes	percent_of_prediction	percent_of_DWPC	metapath
Pancuronium—BCHE—Neurotransmitter Clearance In The Synaptic Cleft—SLC6A3—Gilles de la Tourette syndrome	0.0622	0.0825	CbGpPWpGaD
Pancuronium—SLC22A2—Neurotransmitter Clearance In The Synaptic Cleft—SLC6A3—Gilles de la Tourette syndrome	0.0556	0.0736	CbGpPWpGaD
Pancuronium—SLC22A1—Neurotransmitter Clearance In The Synaptic Cleft—SLC6A3—Gilles de la Tourette syndrome	0.0518	0.0686	CbGpPWpGaD
Pancuronium—SLC22A2—Na+/Cl- dependent neurotransmitter transporters—SLC6A3—Gilles de la Tourette syndrome	0.0278	0.0369	CbGpPWpGaD
Pancuronium—SLC22A1—Na+/Cl- dependent neurotransmitter transporters—SLC6A3—Gilles de la Tourette syndrome	0.0259	0.0344	CbGpPWpGaD
Pancuronium—CHRNB1—midbrain—Gilles de la Tourette syndrome	0.0239	0.0975	CbGeAlD
Pancuronium—CHRNA2—nervous system—Gilles de la Tourette syndrome	0.0211	0.0862	CbGeAlD
Pancuronium—CHRNA2—central nervous system—Gilles de la Tourette syndrome	0.0203	0.083	CbGeAlD
Pancuronium—CHRM3—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.0196	0.026	CbGpPWpGaD
Pancuronium—CHRNA1—brain—Gilles de la Tourette syndrome	0.0195	0.0794	CbGeAlD
Pancuronium—CHRM2—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.0194	0.0257	CbGpPWpGaD
Pancuronium—SLC22A2—Amine compound SLC transporters—SLC6A3—Gilles de la Tourette syndrome	0.0193	0.0256	CbGpPWpGaD
Pancuronium—SLC22A1—Amine compound SLC transporters—SLC6A3—Gilles de la Tourette syndrome	0.018	0.0238	CbGpPWpGaD
Pancuronium—CHRM3—Monoamine GPCRs—DRD3—Gilles de la Tourette syndrome	0.0167	0.0222	CbGpPWpGaD
Pancuronium—CHRM2—Monoamine GPCRs—DRD3—Gilles de la Tourette syndrome	0.0166	0.022	CbGpPWpGaD
Pancuronium—CHRM3—Monoamine GPCRs—DRD4—Gilles de la Tourette syndrome	0.0163	0.0215	CbGpPWpGaD
Pancuronium—CHRNA2—brain—Gilles de la Tourette syndrome	0.0161	0.0659	CbGeAlD
Pancuronium—CHRM2—Monoamine GPCRs—DRD4—Gilles de la Tourette syndrome	0.0161	0.0213	CbGpPWpGaD
Pancuronium—CHRM3—Monoamine GPCRs—DRD2—Gilles de la Tourette syndrome	0.0151	0.0201	CbGpPWpGaD
Pancuronium—CHRNB1—brain—Gilles de la Tourette syndrome	0.015	0.0613	CbGeAlD
Pancuronium—CHRM2—Monoamine GPCRs—DRD2—Gilles de la Tourette syndrome	0.015	0.0199	CbGpPWpGaD
Pancuronium—CHRM3—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	0.0141	0.0186	CbGpPWpGaD
Pancuronium—CHRM2—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	0.0139	0.0185	CbGpPWpGaD
Pancuronium—CHRM3—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	0.0137	0.0181	CbGpPWpGaD
Pancuronium—CHRM2—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	0.0135	0.0179	CbGpPWpGaD
Pancuronium—CHRM3—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	0.0127	0.0169	CbGpPWpGaD
Pancuronium—CHRM2—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	0.0126	0.0167	CbGpPWpGaD
Pancuronium—CHRM2—nervous system—Gilles de la Tourette syndrome	0.0126	0.0514	CbGeAlD
Pancuronium—SLC22A1—nervous system—Gilles de la Tourette syndrome	0.0124	0.0505	CbGeAlD
Pancuronium—CHRM2—central nervous system—Gilles de la Tourette syndrome	0.0121	0.0495	CbGeAlD
Pancuronium—SLC22A1—central nervous system—Gilles de la Tourette syndrome	0.0119	0.0486	CbGeAlD
Pancuronium—CHRND—Transmission across Chemical Synapses—SLC6A3—Gilles de la Tourette syndrome	0.0106	0.0141	CbGpPWpGaD
Pancuronium—CHRM3—Monoamine GPCRs—HTR2A—Gilles de la Tourette syndrome	0.0106	0.014	CbGpPWpGaD
Pancuronium—CHRM2—Monoamine GPCRs—HTR2A—Gilles de la Tourette syndrome	0.0105	0.0139	CbGpPWpGaD
Pancuronium—CHRM3—nervous system—Gilles de la Tourette syndrome	0.0103	0.0419	CbGeAlD
Pancuronium—BCHE—midbrain—Gilles de la Tourette syndrome	0.0102	0.0416	CbGeAlD
Pancuronium—CHRM3—central nervous system—Gilles de la Tourette syndrome	0.00988	0.0403	CbGeAlD
Pancuronium—CHRM2—brain—Gilles de la Tourette syndrome	0.00963	0.0393	CbGeAlD
Pancuronium—SLC22A1—brain—Gilles de la Tourette syndrome	0.00946	0.0386	CbGeAlD
Pancuronium—CHRNA1—Transmission across Chemical Synapses—SLC6A3—Gilles de la Tourette syndrome	0.00904	0.012	CbGpPWpGaD
Pancuronium—CHRM3—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.00891	0.0118	CbGpPWpGaD
Pancuronium—CHRM2—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.00883	0.0117	CbGpPWpGaD
Pancuronium—CHRNA2—Transmission across Chemical Synapses—SLC6A3—Gilles de la Tourette syndrome	0.00859	0.0114	CbGpPWpGaD
Pancuronium—BCHE—nervous system—Gilles de la Tourette syndrome	0.00837	0.0342	CbGeAlD
Pancuronium—CHRND—Neuronal System—SLC6A3—Gilles de la Tourette syndrome	0.00815	0.0108	CbGpPWpGaD
Pancuronium—BCHE—central nervous system—Gilles de la Tourette syndrome	0.00806	0.0329	CbGeAlD
Pancuronium—CHRM3—brain—Gilles de la Tourette syndrome	0.00784	0.032	CbGeAlD
Pancuronium—SLC22A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC6A3—Gilles de la Tourette syndrome	0.00755	0.01	CbGpPWpGaD
Pancuronium—CHRM3—GPCRs, Other—DRD3—Gilles de la Tourette syndrome	0.00744	0.00985	CbGpPWpGaD
Pancuronium—CHRM2—GPCRs, Other—DRD3—Gilles de la Tourette syndrome	0.00736	0.00975	CbGpPWpGaD
Pancuronium—CHRM3—GPCRs, Other—DRD4—Gilles de la Tourette syndrome	0.00722	0.00956	CbGpPWpGaD
Pancuronium—CHRM2—GPCRs, Other—DRD4—Gilles de la Tourette syndrome	0.00715	0.00947	CbGpPWpGaD
Pancuronium—SLC22A1—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC6A3—Gilles de la Tourette syndrome	0.00704	0.00932	CbGpPWpGaD
Pancuronium—CHRNA1—Neuronal System—SLC6A3—Gilles de la Tourette syndrome	0.00693	0.00918	CbGpPWpGaD
Pancuronium—CHRNA2—Neuronal System—SLC6A3—Gilles de la Tourette syndrome	0.00658	0.00872	CbGpPWpGaD
Pancuronium—BCHE—brain—Gilles de la Tourette syndrome	0.0064	0.0261	CbGeAlD
Pancuronium—BCHE—Transmission across Chemical Synapses—SLC6A3—Gilles de la Tourette syndrome	0.00474	0.00628	CbGpPWpGaD
Pancuronium—CHRM3—GPCRs, Other—HTR2A—Gilles de la Tourette syndrome	0.00471	0.00624	CbGpPWpGaD
Pancuronium—CHRM2—GPCRs, Other—HTR2A—Gilles de la Tourette syndrome	0.00466	0.00618	CbGpPWpGaD
Pancuronium—SLC22A2—Transmission across Chemical Synapses—SLC6A3—Gilles de la Tourette syndrome	0.00423	0.00561	CbGpPWpGaD
Pancuronium—SLC22A1—Transmission across Chemical Synapses—SLC6A3—Gilles de la Tourette syndrome	0.00395	0.00523	CbGpPWpGaD
Pancuronium—BCHE—Neuronal System—SLC6A3—Gilles de la Tourette syndrome	0.00363	0.00481	CbGpPWpGaD
Pancuronium—CHRM2—G alpha (i) signalling events—DRD3—Gilles de la Tourette syndrome	0.00345	0.00457	CbGpPWpGaD
Pancuronium—SLC22A2—SLC-mediated transmembrane transport—SLC6A3—Gilles de la Tourette syndrome	0.00343	0.00455	CbGpPWpGaD
Pancuronium—CHRM2—G alpha (i) signalling events—DRD4—Gilles de la Tourette syndrome	0.00335	0.00443	CbGpPWpGaD
Pancuronium—SLC22A2—Neuronal System—SLC6A3—Gilles de la Tourette syndrome	0.00324	0.0043	CbGpPWpGaD
Pancuronium—CHRM3—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.00323	0.00428	CbGpPWpGaD
Pancuronium—CHRM2—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.0032	0.00424	CbGpPWpGaD
Pancuronium—SLC22A1—SLC-mediated transmembrane transport—SLC6A3—Gilles de la Tourette syndrome	0.0032	0.00424	CbGpPWpGaD
Pancuronium—CHRM3—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.00314	0.00415	CbGpPWpGaD
Pancuronium—CHRM2—G alpha (i) signalling events—DRD2—Gilles de la Tourette syndrome	0.00312	0.00413	CbGpPWpGaD
Pancuronium—CHRM2—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.00311	0.00411	CbGpPWpGaD
Pancuronium—CHRM2—SIDS Susceptibility Pathways—HTR2A—Gilles de la Tourette syndrome	0.00303	0.00401	CbGpPWpGaD
Pancuronium—SLC22A1—Neuronal System—SLC6A3—Gilles de la Tourette syndrome	0.00302	0.004	CbGpPWpGaD
Pancuronium—CHRM3—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.00292	0.00387	CbGpPWpGaD
Pancuronium—CHRM2—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.00289	0.00383	CbGpPWpGaD
Pancuronium—CHRM3—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.00277	0.00367	CbGpPWpGaD
Pancuronium—CHRM2—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.00274	0.00363	CbGpPWpGaD
Pancuronium—CHRM3—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.00269	0.00356	CbGpPWpGaD
Pancuronium—CHRM2—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.00266	0.00352	CbGpPWpGaD
Pancuronium—CHRM3—G alpha (q) signalling events—HTR2A—Gilles de la Tourette syndrome	0.00265	0.00351	CbGpPWpGaD
Pancuronium—BCHE—Metabolism—HDC—Gilles de la Tourette syndrome	0.00263	0.00348	CbGpPWpGaD
Pancuronium—CHRM3—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.0025	0.00332	CbGpPWpGaD
Pancuronium—CHRM2—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.00248	0.00328	CbGpPWpGaD
Pancuronium—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—Gilles de la Tourette syndrome	0.00237	0.00314	CbGpPWpGaD
Pancuronium—SLC22A2—Metabolism—HDC—Gilles de la Tourette syndrome	0.00235	0.00311	CbGpPWpGaD
Pancuronium—SLC22A1—Metabolism—HDC—Gilles de la Tourette syndrome	0.00219	0.0029	CbGpPWpGaD
Pancuronium—CHRM3—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.00211	0.00279	CbGpPWpGaD
Pancuronium—CHRM2—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.00209	0.00276	CbGpPWpGaD
Pancuronium—CHRM3—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.00205	0.00271	CbGpPWpGaD
Pancuronium—CHRM3—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.00205	0.00271	CbGpPWpGaD
Pancuronium—CHRM2—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.00203	0.00268	CbGpPWpGaD
Pancuronium—CHRM2—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.00203	0.00268	CbGpPWpGaD
Pancuronium—CHRM3—Metabolism—HDC—Gilles de la Tourette syndrome	0.00202	0.00268	CbGpPWpGaD
Pancuronium—CHRM3—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.00191	0.00252	CbGpPWpGaD
Pancuronium—CHRM2—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.00189	0.0025	CbGpPWpGaD
Pancuronium—CHRM3—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.00175	0.00232	CbGpPWpGaD
Pancuronium—SLC22A2—Transmembrane transport of small molecules—SLC6A3—Gilles de la Tourette syndrome	0.00174	0.00231	CbGpPWpGaD
Pancuronium—CHRM2—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.00174	0.0023	CbGpPWpGaD
Pancuronium—SLC22A1—Transmembrane transport of small molecules—SLC6A3—Gilles de la Tourette syndrome	0.00163	0.00215	CbGpPWpGaD
Pancuronium—CHRM3—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	0.00134	0.00177	CbGpPWpGaD
Pancuronium—CHRM2—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	0.00132	0.00175	CbGpPWpGaD
Pancuronium—CHRM3—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	0.00119	0.00158	CbGpPWpGaD
Pancuronium—CHRM2—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	0.00118	0.00156	CbGpPWpGaD
Pancuronium—CHRM3—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	0.00116	0.00153	CbGpPWpGaD
Pancuronium—CHRM2—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	0.00115	0.00152	CbGpPWpGaD
Pancuronium—CHRM3—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.00108	0.00143	CbGpPWpGaD
Pancuronium—CHRM3—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	0.00108	0.00143	CbGpPWpGaD
Pancuronium—CHRM2—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.00107	0.00142	CbGpPWpGaD
Pancuronium—CHRM2—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	0.00107	0.00141	CbGpPWpGaD
Pancuronium—CHRM3—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.00105	0.00139	CbGpPWpGaD
Pancuronium—CHRM2—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.00104	0.00138	CbGpPWpGaD
Pancuronium—CHRM3—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.000978	0.0013	CbGpPWpGaD
Pancuronium—CHRM2—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.000969	0.00128	CbGpPWpGaD
Pancuronium—CHRM3—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	0.000754	0.000999	CbGpPWpGaD
Pancuronium—CHRM2—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	0.000747	0.00099	CbGpPWpGaD
Pancuronium—CHRM3—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	0.000685	0.000907	CbGpPWpGaD
Pancuronium—CHRM2—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	0.000678	0.000899	CbGpPWpGaD
Pancuronium—CHRM3—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.000639	0.000846	CbGpPWpGaD
Pancuronium—CHRM2—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.000633	0.000838	CbGpPWpGaD
Pancuronium—CHRM3—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.00062	0.000822	CbGpPWpGaD
Pancuronium—CHRM2—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.000614	0.000814	CbGpPWpGaD
Pancuronium—CHRM3—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.000578	0.000765	CbGpPWpGaD
Pancuronium—CHRM2—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.000572	0.000758	CbGpPWpGaD
Pancuronium—CHRM3—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.000405	0.000536	CbGpPWpGaD
Pancuronium—CHRM2—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.000401	0.000531	CbGpPWpGaD
